Physician profile
Cassandra L Doss
NPI 1649747403
$1,409.72
in general payments reported to CMS, 2019-2025
26 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $676 · 2022: $527 · 2023: $45.01 · 2024: $13.90 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $175.47 | 2021-2025 | |
| Amgen INC. | $132.82 | 2021-2023 | Repatha, Otezla |
| Lilly USA, LLC | $112.45 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $110.75 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $105.12 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.71 | 2021-2023 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $74.81 | 2021 | |
| Novo Nordisk INC | $71.92 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $68.72 | 2022 | |
| Amarin Pharma, INC. | $66.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.65 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.63 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $39.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.71 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $30.45 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $30.13 | 2025 | Daxxify |
| Sanofi-Aventis U.S. LLC | $26.11 | 2021-2022 | |
| Daiichi Sankyo INC. | $17.61 | 2021 | |
| Glaxosmithkline, LLC. | $17.28 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.93 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.54 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.51 | 2021 | |
| Adlon Therapeutics L.P. | $14.47 | 2021 | |
| Phadia US INC. | $13.90 | 2024 | Immunocap |
| Virtus Pharmaceuticals LLC | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Doss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.